Betamethasone sodium phosphate

16beta;-methyl-11beta;,17alpha;,21-trihydroxy-9alpha;fluoro-pregnane-1,4-diene-3,20-dione-21-phosphate disodium salt

1. Nonsteroidal anti-inflammatory analgesics can enhance its ulcerogenic effect. 2. It can enhance the hepatotoxicity of acetaminophen. 3. When used in combination with amphotericin B or carbonic anhydrase inhibitors, it can aggravate hypokalemia. Long-term use with carbonic anhydrase inhibitors can easily lead to hypocalcemia and osteoporosis. 4. When used in combination with protein anabolic hormones, it can increase the incidence of edema and aggravate acne. 5. Long-term use with anticholinergics (such as atropine) can cause increased intraocular pressure. 6. Tricyclic antidepressants can aggravate the mental symptoms caused by it. 7. When used in combination with hypoglycemic drugs such as insulin, the dose of hypoglycemic drugs should be appropriately adjusted because it can increase blood sugar in diabetic patients. 8. Thyroid hormones can increase its metabolic clearance rate, so when thyroid hormones or antithyroid drugs are used in combination with it, the dose of the latter should be appropriately adjusted. 9. When used in combination with contraceptives or estrogen preparations, it can enhance its therapeutic effects and adverse reactions. 10. When used in combination with cardiac glycosides, it can increase the occurrence of digitalis toxicity and arrhythmia. 11 When used in combination with potassium-excreting diuretics, it can cause severe hypokalemia and weaken the sodium-excreting and diuretic effects of diuretics due to water and sodium retention. 12 When used in combination with ephedrine, its metabolic clearance can be enhanced. 13 When used in combination with immunosuppressants, it can increase the risk of infection and may induce lymphoma or other lymphoproliferative diseases. 14 It can increase the metabolism and excretion of isoniazid in the liver, and reduce the blood concentration and efficacy of isoniazid. 15 It can promote the metabolism of mexiletine in the body and reduce the blood concentration. 16 When used in combination with salicylates, it can reduce the concentration of plasma salicylate. 17 When used in combination with growth hormone, it can inhibit the latter's growth-promoting effect.

This product is a sterile suspension injection of betamethasone dipropionate and betamethasone sodium phosphate, and contains a sterilization buffer and a preservative.

Concomitant use of phenobarbital, rifampin, phenytoin, or ephedrine may promote the metabolism of corticosteroids, thereby reducing their efficacy. Patients taking corticosteroids and estrogens should be observed for symptoms of excessive corticosteroid effects. Concomitant use of corticosteroids and potassium-wasting diuretics may aggravate hypokalemia; concurrent use of corticosteroids and cardiac glycosides may increase the risk of hypokalemia-related arrhythmias or digitalis poisoning. Corticosteroids may promote potassium loss caused by amphotericin B. Serum electrolytes, especially potassium levels, should be closely monitored in all patients taking any of the above concomitant medications. Concomitant use of corticosteroids and coumarin anticoagulants may increase or decrease the anticoagulant effect, so the drug dose may need to be adjusted. The combined effects of nonsteroidal anti-inflammatory drugs or ethanol and corticosteroids may increase the incidence or severity of gastrointestinal ulcers. Corticosteroids may reduce the concentration of salicylates in the blood. For patients with hypoprothrombin, the combined use of aspirin and corticosteroids should be used with caution. When corticosteroids are used in patients with diabetes, the dosage of the antidiabetic medication may need to be adjusted. Concurrent glucocorticoid therapy can inhibit the body's response to growth hormone.